Company Overview Management Geographical Map
CEO & CTO
Significant and highly qualified expertise in the field of pharmaceutical development

Dae-Kee Kim,

Ph.D.

Education

1982–1986: State University of New York at Buffalo. Ph.D. in Medicinal Chemistry

1980–1982: Seoul National University, Korea. M.S. Pharmaceutical Chemistry

1973–1977: Seoul National University, Korea. B.S. Pharmacy


Career

2015 03 - Present: CEO/CTO, EWHA DrugDesignHouse, Co., Ltd., Korea

2022 03 - Present: Distinguished Professor, College of Pharmacy, Ewha Womans University, Korea

2008 11 - 2013 11: Project Manager, Global Anti-Cancer Drug Development Group, Ministry of Education, Science and Technology, Korea

2002 9 - 2022 02: Professor, College of Pharmacy, Ewha Womans University, Korea

2000 7 - 2005 11: CEO, In2Gen Co.,Ltd., Korea

1997 1 - 2001 3: Director, Life Science Research Center, SK Chemicals (previously Sunkyong Industries), Korea

1989 1 - 1996 12: Research Associate, Sunkyong Industries, Life Science Research Center, Korea

1987 10 - 1988 11: Senior Researcher, Korea Research Institute of Chemical Technology, Korea

1986 10 - 1987 9: Postdoctoral fellow, ICN Nucleic Acid Research Institute, Costa Mesa, California, USA


Achievement

2022 Development of an intestine-specific, partial FXR agonist, EW-8198 (EWHA DrugDesignHouse/Ewha Womans University)

2021 Out-licensing the right of EW-7197 (Vactosertib) for use of IBD to Biophammer, Inc. (EWHA DrugDesignHouse)

2016 Approval of antihemophilic Factor VIII recombinant, Apstyla¢ç from US FDA (2016.05) and EMA (2016.11) (In2Gen/SK Chemicals/CSL)

2015 Out-licensing the right of EW-7197 (Vactosertib) for use of all indications except oncology to EWHA DrugDesignHouse (Ewha Womans University)

2012 Out-licensing the right of EW-7197 (Vactosertib) for use of oncology indication to Medpacto, Inc. (Ewha Womans University)

2007 Approval of a PDE5 Inhibitor, M¡¤Vix¢ç (Mirodenafil) from KFDA (In2Gen/SK Chemicals)

1999 Approval of an anticancer platinum complex, Sunpla¢ç from KFDA (SK Chemicals)



Honors & Awards

2022 Distinguished professor (Ewha Womans University)

2019 Excellent professor of technology commercialization (Ewha Womans University)

2018 Plenary speaker, 2018 Fall International Convention of The Pharmaceutical Society of Korea

2002 Research Grand Prize in the 2002 Health Industry and Technology Exhibition (Ministry of Health and Welfare, Korea)

2000 DongAm New Drug Development Prize (Yakup News, Korea)

1999 New Drug Development Prize (Korea Drug Research Association)

1999 Scientist of the Month Award (Korea Science and Engineering Foundation)

1999 New Knowledge Man Patent Prize (Korean Intellectual Property Office)

1999 Presidential Prize in the Korea Industry and Technology Exhibition (Ministry of Commerce, Industry and Energy, Korea)

1999 Dasan Technology Grand Prize (The Korean Economic Daily)

1995 WIPO Prize (Korea Invention Promotion Association)

1995 Technology Progress Prize (Korean Chemical Society)

1995 Distinguishing Patent Prize (JungAng Ilbo, Korea)




KEY MEMBERS


Kyuchoon Hwang

Ph.D.


Chief Operating Officer
Chief Financial Officer

Soyeon Shim

Ph.D.


Chief Regulatory Officer

Kyungnam Kim

Lawyer


Auditor